Navigation Links
A drug in vogue to deccelerate the course of Alzheimer's

Alzheimer’s disease continues to fuel research, as the incidence is likely to increase in the future. A new drug has been developed to slow the course of Alzheimer's disease. There is a special chemical called glutamate, which is one of the brain’s messenger and this chemical//is regulated by a drug called Memantine. Learning and memory are the fields, which are enabled by the chemical glutamate. This happens when glutamate is in its normal concentration. Its concentration can increase or decrease according to the level of Alzheimer's disease.

Available treatments for Alzheimer's that have proven effective at treating mild to moderate stages of the disease are aimed at a different chemical system in the brain, the cholinergic system. Memantine has been approved for use in Germany for more than 10 years.

The Food and Drug Administration is reviewing its safety and efficacy for possible U.S. sale of this drug. Approval could happen by this fall. Findings from a randomized, double-blind study of the drug in 252 patients were published in the April 3 New England Journal of Medicine.

Patients who took Memantine seemed to decline about half as much during the six-month trial as would ordinarily be expected, said Barry Reisberg, MD, professor of psychiatry at New York University School of Medicine, who led the study. Another issue that must be teased out is whether antioxidants in a pill are as beneficial as those in food, noted Paula Bickford, PhD, professor of neurosurgery at the University of South Florida, Tampa.
'"/>




Page: 1

Related medicine news :

1. Sun screen in vogue: for fashion and for health!
2. Postpone intercourse after childbirth
3. Satisfied Sexual Intercourse for Impotence men with Penile Prosthesis
4. Schools set to offer Japanese language course
5. A New Study Discredits The Myth Of Sexual Intercourse Late In Pregnancy Speeds Labour & Delivery
6. Indias Law on Homosexuality Needs Recourse - Hampers HIV Prevention
7. Timing of First Intercourse is Vital
8. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
9. Decrease in testosterone levels lead to Alzheimers
10. Smokers are prone to Alzheimers
11. Over-The-Counter Drugs May Prevent Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... will lecture to primary eye care practitioners on the latest breakthroughs in the ... 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New ... the region, is launching a charity drive to raise awareness of heart disease and ... killer in America, and is responsible for 1 in every 4 deaths at the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... Tyler, TX (PRWEB) , ... January 17, 2017 ... ... serving Texas families from two offices in Tyler, has announced the latest beneficiary ... Red Ribbon Wish Network, a nonprofit organization dedicated to fulfilling the dreams of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene ... vice president, research and pharmaceutical development at Tocagen, will present at ... held Jan. 17-20 in Miami . ... ... manufacturing for replicating viruses - what to do when and why ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
(Date:1/17/2017)... , Jan. 17, 2017 Immune Pharmaceuticals (NASDAQ: ... company, announced today that it will hold a Satellite Symposium ... Acute Leukemias (ISAL) XVI in Munich, Germany ... "Reinforcing the Efficacy of Immunotherapy for the maintenance of ... on Monday February 20 th , 2017 from 12:45 – ...
Breaking Medicine Technology: